Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Paclitaxel/Carboplatin in Advanced Gynaecological Malignancies
NCT02182245Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2005
- Primary completion
- Jan 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label trial of nintedanib in ovarian cancer, endometrial cancer (EC), uterine sarcoma and 5 more (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 126 days and Incidence and intensity of adverse events up to 9 months. Started Oct 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
ovarian cancerendometrial cancer (EC)uterine sarcomaMalignant mixed Müllerian tumor (MMMT)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02182245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182245.